Concepedia

Publication | Closed Access

Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1‐6 and compensated cirrhosis or advanced fibrosis

DOI

51

Citations

17

References

2017

Year

Tarik Asselah, Stefan Bourgeois, Stephen Pianko, Stefan Zeuzem, Mark Sulkowski, Graham R. Foster, Lingling Han, John McNally, Anu Osinusi, Diana M. Brainard,
Liver International

Abstract

Sofosbuvir plus velpatasvir is highly effective and safe for treating patients with hepatitis C virus genotypes 1, 2, 3, 4, 5 or 6 and advanced fibrosis or compensated cirrhosis.

References

YearCitations

Page 1